Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

ACCREDITED SYMPOSIA

EARLY CAREER INVOLVEMENT

101 - TARGETING INFLAMMATION - ARE WE APPROACHING THE TIPPING POINT?

Thursday, October 24, 2024
2:00 PM – 3:00 PM PT
Room: 118-120

On-Demand Early Career Involvement
Join us for an accredited symposium on the role of inflammation in cardiovascular diseases (CVD), presented at the Canadian Cardiovascular Congress 2024.

This 1-hour live symposium aims to provide cardiologists with a comprehensive understanding of the interconnectivity between inflammation and various cardiovascular conditions such as atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and heart failure with preserved ejection fraction (HFpEF).

The symposium will include case presentations, discussions on pathophysiological mechanisms, and emerging therapeutic approaches targeting inflammation. Participants will gain insights into the importance of residual inflammation in disease progression and evaluate current and novel anti-inflammatory strategies.

The sessions will cover topics such as the inflammatory link in ASCVD and CKD, targeting inflammation in cardiovascular diseases, and the bidirectional relationship between systemic inflammation and HFpEF.

Learning Objectives:

At the end of this session participants will be able to:
  • Analyze the interconnectivity between inflammation and cardiovascular diseases, such as ASCVD, CKD, and HFpEF;
  • Evaluate the importance of residual inflammation in disease progression; and
  • Examine the emerging therapies in HFpEF, inflammation, and cardiometabolic syndrome.
Disclosure(s):
Subodh Verma, MD PhD FRCSC FAHA FCCS FCAHS: Amarin: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astrazeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Humber River Health: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); S & L Solutions Event Management Inc: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sun Pharma: Speaker/Honoraria (Ongoing)
Anique Ducharme, MD, MSc, FCCS, FACCC: Abbott medical: Co-PI EVOLVE MR trial (Ongoing), Outreach conference in advanced heart failure (Ongoing); Astra-Zeneca: Guidelines conference sponsored by AZ (Ongoing), SYMPHONY trial - earliy detection of heart failure in the community (Ongoing); BridgeBio: Attribute TTR trial (Ongoing); Canadian Heart failure Society: Past president (member of the Executive board, voluntary work) and honorarium for conferences (Ongoing); Merck: National Leader, VITOR trial (Ongoing); Novartis: Guidelines conference sponsored by Novartis (Ongoing), HF-iDOC, PARTHENON (Ongoing); NovoNordisk: Conferences/satellite symposium at HFA (Ongoing), HERMES trial - Member of the steering Committe (Ongoing)